312 related articles for article (PubMed ID: 9693271)
1. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals.
Zangerle R; Steinhuber S; Sarcletti M; Dierich MP; Wachter H; Fuchs D; Möst J
Int Arch Allergy Immunol; 1998 Jul; 116(3):228-39. PubMed ID: 9693271
[TBL] [Abstract][Full Text] [Related]
2. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection.
Zangerle R; Fuchs D; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Dierich MP; Möst J
Clin Immunol Immunopathol; 1994 Sep; 72(3):328-34. PubMed ID: 7914841
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
4. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study.
Stein DS; Lyles RH; Graham NM; Tassoni CJ; Margolick JB; Phair JP; Rinaldo C; Detels R; Saah A; Bilello J
J Infect Dis; 1997 Nov; 176(5):1161-7. PubMed ID: 9359714
[TBL] [Abstract][Full Text] [Related]
5. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection.
Zangerle R; Gallati H; Sarcletti M; Wachter H; Fuchs D
Immunol Lett; 1994 Jul; 41(2-3):229-34. PubMed ID: 8002043
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.
Fahey JL; Taylor JM; Manna B; Nishanian P; Aziz N; Giorgi JV; Detels R
AIDS; 1998 Sep; 12(13):1581-90. PubMed ID: 9764776
[TBL] [Abstract][Full Text] [Related]
8. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
Liu Z; Cumberland WG; Hultin LE; Prince HE; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):83-92. PubMed ID: 9358102
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy.
Savès M; Morlat P; Chêne G; Peuchant E; Pellegrin I; Bonnet F; Bernard N; Lacoste D; Salamon R; Beylot J
Clin Immunol; 2001 Jun; 99(3):347-52. PubMed ID: 11358430
[TBL] [Abstract][Full Text] [Related]
11. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R
AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448
[TBL] [Abstract][Full Text] [Related]
13. Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection.
Aziz N; Nishanian P; Taylor JM; Mitsuyasu RT; Jacobson JM; Dezube BJ; Lederman MM; Detels R; Fahey JL
J Infect Dis; 1999 Apr; 179(4):843-8. PubMed ID: 10068579
[TBL] [Abstract][Full Text] [Related]
14. Immune activation markers and AIDS prognosis.
Osmond DH; Shiboski S; Bacchetti P; Winger EE; Moss AR
AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808
[TBL] [Abstract][Full Text] [Related]
15. 'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses.
Lederman MM; Kalish LA; Asmuth D; Fiebig E; Mileno M; Busch MP
AIDS; 2000 May; 14(8):951-8. PubMed ID: 10853976
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome.
Rizzardi GP; Barcellini W; Tambussi G; Lillo F; Malnati M; Perrin L; Lazzarin A
AIDS; 1996 Nov; 10(13):F45-50. PubMed ID: 8931778
[TBL] [Abstract][Full Text] [Related]
17. [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].
Halota W; Jaruga B; Pawłowska M
Pol Merkur Lekarski; 2002 Aug; 13(74):126-8. PubMed ID: 12420343
[TBL] [Abstract][Full Text] [Related]
18. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
Mellors JW; Muñoz A; Giorgi JV; Margolick JB; Tassoni CJ; Gupta P; Kingsley LA; Todd JA; Saah AJ; Detels R; Phair JP; Rinaldo CR
Ann Intern Med; 1997 Jun; 126(12):946-54. PubMed ID: 9182471
[TBL] [Abstract][Full Text] [Related]
19. Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group.
Ashton LJ; Carr A; Cunningham PH; Roggensack M; McLean K; Law M; Robertson M; Cooper DA; Kaldor JM
AIDS Res Hum Retroviruses; 1998 Jan; 14(2):117-21. PubMed ID: 9462921
[TBL] [Abstract][Full Text] [Related]
20. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
